Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 267-274 |
| Number of pages | 8 |
| Journal | ESC heart failure |
| Volume | 5 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jan 1 2018 |
Fingerprint
Keywords
- Heart failure
- Hyperkalaemia
- Mineralocorticoid receptor antagonists
- Worsening renal function
Cite this
Mineralocorticoid receptor antagonists for heart failure. / Bruno, Noemi; Sinagra, Gianfranco; Paolillo, Stefania; Bonomi, Alice; Corrà, Ugo; Piepoli, Massimo; Veglia, Fabrizio; Salvioni, Elisabetta; Lagioia, Rocco; Metra, Marco; Limongelli, Giuseppe; Cattadori, Gaia; Scardovi, Angela B.; Carubelli, Valentina; Scrutino, Domenico; Badagliacca, Roberto; Guazzi, Marco; Raimondo, Rosa; Gentile, Piero; Magrì, Damiano; Correale, Michele; Parati, Gianfranco; Re, Federica; Cicoira, Mariantonietta; Frigerio, Maria; Bussotti, Maurizio; Vignati, Carlo; Oliva, Fabrizio; Mezzani, Alessandro; Vergaro, Giuseppe; Di Lenarda, Andrea; Passino, Claudio; Sciomer, Susanna; Pacileo, Giuseppe; Ricci, Roberto; Contini, Mauro; Apostolo, Anna; Palermo, Pietro; Mapelli, Massimo; Carriere, Cosimo; Clemenza, Francesco; Binno, Simone; Belardinelli, Romualdo; Lombardi, Carlo; Perrone Filardi, Pasquale; Emdin, Michele; Agostoni, Piergiuseppe.
In: ESC heart failure, Vol. 5, No. 3, 01.01.2018, p. 267-274.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Mineralocorticoid receptor antagonists for heart failure
AU - Bruno, Noemi
AU - Sinagra, Gianfranco
AU - Paolillo, Stefania
AU - Bonomi, Alice
AU - Corrà, Ugo
AU - Piepoli, Massimo
AU - Veglia, Fabrizio
AU - Salvioni, Elisabetta
AU - Lagioia, Rocco
AU - Metra, Marco
AU - Limongelli, Giuseppe
AU - Cattadori, Gaia
AU - Scardovi, Angela B.
AU - Carubelli, Valentina
AU - Scrutino, Domenico
AU - Badagliacca, Roberto
AU - Guazzi, Marco
AU - Raimondo, Rosa
AU - Gentile, Piero
AU - Magrì, Damiano
AU - Correale, Michele
AU - Parati, Gianfranco
AU - Re, Federica
AU - Cicoira, Mariantonietta
AU - Frigerio, Maria
AU - Bussotti, Maurizio
AU - Vignati, Carlo
AU - Oliva, Fabrizio
AU - Mezzani, Alessandro
AU - Vergaro, Giuseppe
AU - Di Lenarda, Andrea
AU - Passino, Claudio
AU - Sciomer, Susanna
AU - Pacileo, Giuseppe
AU - Ricci, Roberto
AU - Contini, Mauro
AU - Apostolo, Anna
AU - Palermo, Pietro
AU - Mapelli, Massimo
AU - Carriere, Cosimo
AU - Clemenza, Francesco
AU - Binno, Simone
AU - Belardinelli, Romualdo
AU - Lombardi, Carlo
AU - Perrone Filardi, Pasquale
AU - Emdin, Michele
AU - Agostoni, Piergiuseppe
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Aims: Mineralocorticoid receptor antagonists (MRAs) have been demonstrated to improve outcomes in reduced ejection fraction heart failure (HFrEF) patients. However, MRAs added to conventional treatment may lead to worsening of renal function and hyperkalaemia. We investigated, in a population-based analysis, the long-term effects of MRA treatment in HFrEF patients. Methods and results: We analysed data of 6046 patients included in the Metabolic Exercise Cardiac Kidney Index score dataset. Analysis was performed in patients treated (n = 3163) and not treated (n = 2883) with MRA. The study endpoint was a composite of cardiovascular death, urgent heart transplantation, or left ventricular assist device implantation. Ten years' survival was analysed through Kaplan–Meier, compared by log-rank test and propensity score matching. At 10 years' follow-up, the MRA-untreated group had a significantly lower number of events than the MRA-treated group (P
AB - Aims: Mineralocorticoid receptor antagonists (MRAs) have been demonstrated to improve outcomes in reduced ejection fraction heart failure (HFrEF) patients. However, MRAs added to conventional treatment may lead to worsening of renal function and hyperkalaemia. We investigated, in a population-based analysis, the long-term effects of MRA treatment in HFrEF patients. Methods and results: We analysed data of 6046 patients included in the Metabolic Exercise Cardiac Kidney Index score dataset. Analysis was performed in patients treated (n = 3163) and not treated (n = 2883) with MRA. The study endpoint was a composite of cardiovascular death, urgent heart transplantation, or left ventricular assist device implantation. Ten years' survival was analysed through Kaplan–Meier, compared by log-rank test and propensity score matching. At 10 years' follow-up, the MRA-untreated group had a significantly lower number of events than the MRA-treated group (P
KW - Heart failure
KW - Hyperkalaemia
KW - Mineralocorticoid receptor antagonists
KW - Worsening renal function
U2 - 10.1002/ehf2.12244
DO - 10.1002/ehf2.12244
M3 - Article
VL - 5
SP - 267
EP - 274
JO - ESC heart failure
JF - ESC heart failure
SN - 2055-5822
IS - 3
ER -